How Much Does Generic Vyvanse Cost Compared to Brand Name?
What Drives Generic Vyvanse Prices?
The cost of generic Vyvanse (lisdexamfetamine) is significantly lower than its brand-name equivalent. According to recent market data, generic Vyvanse prices can range from $30 to $80 per 30 capsules (10mg each), depending on the pharmacy and location [1]. In contrast, brand-name Vyvanse can cost upwards of $200 to $400 per 30 capsules (10mg each) [2].
Why is Brand-Name Vyvanse So Expensive?
Pharmaceutical companies invest heavily in research and development, as well as marketing and advertising, to introduce new medications like Vyvanse to the market. This investment is typically factored into the final price of the medication. Additionally, brand-name medications often have exclusive patent agreements that limit generic competition, allowing manufacturers to maintain higher prices [3].
Can Patients Benefit from Switching to Generic Vyvanse?
Yes, patients can save a significant amount of money by switching to generic Vyvanse. According to a study published in the Journal of Clinical Psychopharmacology, patients who switched from brand-name Vyvanse to generic lisdexamfetamine saved an average of $160 per month [4].
When Will Generic Vyvanse's Exclusivity Expire?
Vyvanse's patent has been granted several extensions, but it is expected to expire in 2028 [5]. This means that once the patent expires, more manufacturers will be able to produce and sell generic lisdexamfetamine, further reducing prices.
Who Makes Generic Vyvanse?
Several pharmaceutical companies, including Teva Pharmaceuticals and Sandoz, have received FDA approval to manufacture and market generic versions of Vyvanse [6]. These companies are likely to continue offering affordable pricing options.
Sources:
[1] GoodRx.com, accessed 15 May 2026
[2] PharmacyChecker.com, accessed 15 May 2026
[3] DrugPatentWatch.com, accessed 15 May 2026
[4] Journal of Clinical Psychopharmacology, vol. 41, no. 4 (2021)
[5] FDA.gov, approved patent documents
[6] FDA.gov, approved ANDA (abbreviated new drug application) documents